NIH Reporter #5R01CA266478-05

Research Grant for Development of Prolidase Inhibitors for Acute Myeloid Leukemia (AML)

This opportunity is a research grant solicitation from the National Cancer Institute (NCI), part of the NIH, focused on developing prolidase (PEPD) inhibitors for Acute Myeloid Leukemia (AML). - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health (NIH) - Research to be conducted at Sloan-Kettering Institute for Cancer Research, New York, NY - OEMs and Vendors: - No specific Original Equipment Manufacturers (OEMs) or vendors are named in the solicitation - Products/Services Requested: - Research and development services for prolidase (PEPD) inhibitors as therapeutic agents for AML - Key objectives include: - Optimization of PEPD inhibitors - Investigation of mechanisms of action - Efficacy testing in mouse models - Unique or Notable Requirements: - Focus on translational research for new AML therapies - No unique license or classification requirements specified - Opportunity classified under NAICS code 541712 (Research and Development in the Physical, Engineering, and Life Sciences) - Estimated contract value is $609,576

Description

This is a research grant opportunity focused on developing PEPD inhibitors as therapeutic agents for Acute Myeloid Leukemia (AML). The project involves three specific aims: optimizing inhibitors, understanding mechanisms, and testing in mouse models. The award is multiyear, with a start date of March 1, 2026, and an end date of February 28, 2027. The research is conducted by the Sloan-Kettering Institute for Cancer Research in New York, NY.

View original listing